| 2026-08-11 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-05 | Press release | Press Release |
| 2026-07-29 | Press release | Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 |
| 2026-07-10 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-01 | Presentation | Download PDF file, (opens in new window) |
| 2026-06-14 | Press release | Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibro |
| 2026-06-11 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-04 | Press release | Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans P |
| 2026-05-30 | Press release | Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Cong |
| 2026-05-12 | Press release | Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible |
| 2026-05-11 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-06 | Press release | Press Release of Q1 2026, aspx file, (opens in new window) |
| 2026-05-06 | Press release | Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 |
| 2026-05-04 | Press release | Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Ch |
| 2026-05-04 | Press release | Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with |
| 2026-05-03 | Press release | Mirum - VISTAS Phase 2b Topline Results Open Event Link, PDF file, May 4, 2026, (opens in new window) |
| 2026-04-27 | Press release | Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic H |
| 2026-04-10 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-16 | Press release | Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholest |
| 2026-03-11 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-05 | Press release | Mirum Pharmaceuticals Completes AZURE-1 Enrollment and AZURE-4 Screening in Phase 3 Program of brelovitug in Chronic Hep |
| 2026-02-25 | Press release | Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on Februar |
| 2026-02-25 | Press release | Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update |
| 2026-02-23 | Press release | Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 2026-02-10 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-01-26 | Press release | Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease |
| 2026-01-12 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-01-07 | Press release | Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-12-19 | Press release | Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX |
| 2025-12-10 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-12-08 | Press release | Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in R |
| 2025-12-07 | Presentation | Mirum Pharmaceuticals Business Update Call |
| 2025-12-01 | Press release | Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragil |
| 2025-11-25 | Press release | Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 2025-11-10 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-11-07 | Press release | Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical P |
| 2025-11-04 | Press release | Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 |
| 2025-11-03 | Press release | Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 2025-10-10 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2025-09-10 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |